Celgene Corp. Company Profile (NASDAQ:CELG)

About Celgene Corp.

Celgene Corp. logoCelgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company's primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company's clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CELG
  • CUSIP: 15102010
Key Metrics:
  • Previous Close: $107.40
  • 50 Day Moving Average: $109.2800
  • 200 Day Moving Average: $105.2690
  • 52-Week Range: $93.05 - $128.39
  • Trailing P/E Ratio: 44.6662
  • Foreward P/E Ratio: 16.46
  • P/E Growth: 0.8500
  • Market Cap: $81.91B
  • Outstanding Shares: 775,114,000
  • Beta: 1.31
  • Net Margins: 18.95%
  • Return on Equity: 67.06%
  • Return on Assets: 13.74%
  • Debt-to-Equity Ratio: 2.58%
  • Current Ratio: 4.61%
  • Quick Ratio: 4.37%
Additional Links:
Companies Related to Celgene Corp.:

Analyst Ratings

Consensus Ratings for Celgene Corp. (NASDAQ:CELG) (?)
Ratings Breakdown: 3 Hold Ratings, 23 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $139.22 (31.55% upside)

Analysts' Ratings History for Celgene Corp. (NASDAQ:CELG)
DateFirmActionRatingPrice TargetDetails
9/18/2016Canaccord GenuitySet Price TargetBuy$156.00View Rating Details
9/16/2016Bank of America Corp.Reiterated RatingBuy$128.00View Rating Details
9/13/2016Robert W. BairdReiterated RatingOutperform$162.00View Rating Details
9/13/2016BMO Capital MarketsReiterated RatingOutperform$141.00View Rating Details
9/13/2016Jefferies GroupReiterated RatingBuy$137.00View Rating Details
9/12/2016Cowen and CompanyReiterated RatingOutperform$150.00View Rating Details
9/12/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details
9/12/2016Leerink SwannReiterated RatingMarket Perform$135.00View Rating Details
9/12/2016Morgan StanleyReiterated RatingEqual Weight$120.00View Rating Details
9/7/2016ArgusReiterated RatingBuy$155.00View Rating Details
8/21/2016BTIG ResearchReiterated RatingBuy$138.00View Rating Details
8/19/2016JPMorgan Chase & Co.Reiterated RatingOverweight$136.00View Rating Details
8/2/2016Stifel NicolausReiterated RatingBuy$138.00View Rating Details
7/26/2016RBC Capital MarketsReiterated RatingBuyView Rating Details
7/12/2016Credit Suisse Group AGReiterated RatingOutperform$140.00View Rating Details
7/6/2016JMP SecuritiesReiterated RatingBuy$152.00View Rating Details
6/13/2016Barclays PLCReiterated RatingPositiveView Rating Details
6/8/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details
5/25/2016William BlairReiterated RatingOutperformView Rating Details
4/28/2016Raymond James Financial Inc.Reiterated RatingBuyView Rating Details
4/28/2016SunTrust Banks Inc.Reiterated RatingBuy$145.00 -> $147.00View Rating Details
2/25/2016Citigroup Inc.Initiated CoverageBuy$130.00View Rating Details
2/22/2016Goldman Sachs Group Inc.Lower Price Target$90.00 -> $83.00View Rating Details
1/29/2016Royal Bank Of CanadaLower Price TargetOutperform$150.00 -> $135.00View Rating Details
1/22/2016Wells Fargo & Co.Reiterated RatingOutperformView Rating Details
1/14/2016Standpoint ResearchInitiated CoverageBuy$130.00View Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral -> NeutralView Rating Details
7/25/2015NomuraReiterated RatingBuy$165.00 -> $167.00View Rating Details
7/15/2015Deutsche Bank AGBoost Price TargetBuy$160.00 -> $175.00View Rating Details
7/2/2015Sanford C. BernsteinReiterated RatingBuy$154.00View Rating Details
1/30/2015S&P Equity ResearchReiterated RatingStrong-BuyView Rating Details
(Data available from 9/29/2014 forward)


Earnings History for Celgene Corp. (NASDAQ:CELG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/28/2016Q216$1.39$1.44$2.70 billion$2.74 billionViewListenView Earnings Details
4/28/2016Q116$1.29$1.32$2.59 billion$2.51 billionViewListenView Earnings Details
1/28/2016Q415$1.22$1.18$2.54 billion$2.54 billionViewListenView Earnings Details
11/5/2015Q315$1.22$1.23$2.40 billion$2.33 billionViewN/AView Earnings Details
7/23/2015Q215$1.08$1.23$2.24 billion$2.28 billionViewListenView Earnings Details
4/30/2015Q115$1.06$1.07$2.11 billion$2.08 billionViewN/AView Earnings Details
1/29/2015Q414$0.99$1.01$2.08 billion$2.09 billionViewN/AView Earnings Details
10/23/2014Q314$0.95$0.97$1.96 billion$1.96 billionViewListenView Earnings Details
7/24/2014Q214$0.89$0.90$1.85 billion$1.87 billionViewN/AView Earnings Details
4/24/2014Q114$1.65$1.67$1.77 billion$1.71 billionViewN/AView Earnings Details
1/30/2014Q413$1.54$1.51$1.72 billion$1.76 billionViewListenView Earnings Details
10/24/2013Q313$1.54$1.56$1.64 billion$1.67 billionViewN/AView Earnings Details
7/25/2013Q2 2013$1.44$1.52$1.54 billion$1.56 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.35$1.37$1.47 billion$1.43 billionViewListenView Earnings Details
1/24/2013Q4 2012$1.31$1.32$1.45 billion$1.42 billionViewListenView Earnings Details
10/25/2012$1.26$1.29ViewN/AView Earnings Details
7/26/2012$1.19$1.22ViewN/AView Earnings Details
4/26/2012$1.13$1.08ViewN/AView Earnings Details
1/26/2012$1.06$1.05ViewN/AView Earnings Details
10/27/2011$0.95$1.02ViewN/AView Earnings Details
7/28/2011$0.85$0.89ViewN/AView Earnings Details
4/28/2011$0.80$0.83ViewN/AView Earnings Details
1/27/2011$0.73$0.73ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Celgene Corp. (NASDAQ:CELG)
Current Year EPS Consensus Estimate: $5.11 EPS
Next Year EPS Consensus Estimate: $6.43 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$1.09$1.09$1.09
Q2 20162$1.25$1.26$1.26
Q3 20162$1.28$1.32$1.30
Q4 20162$1.35$1.39$1.37
(Data provided by Zacks Investment Research)


Dividend History for Celgene Corp. (NASDAQ:CELG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Celgene Corp. (NASDAQ:CELG)
Insider Ownership Percentage: 0.97%
Institutional Ownership Percentage: 77.75%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/23/2016Richard W BarkerDirectorSell20,000$110.82$2,216,400.00View SEC Filing  
9/15/2016Gilla KaplanDirectorSell9,710$106.44$1,033,532.40View SEC Filing  
8/23/2016James J LoughlinDirectorSell27,500$114.10$3,137,750.00View SEC Filing  
8/22/2016Michael D CaseyDirectorSell43,134$114.01$4,917,707.34View SEC Filing  
7/28/2016Robert J HuginInsiderSell100,000$110.00$11,000,000.00View SEC Filing  
6/20/2016Robert J HuginInsiderSell75,000$100.16$7,512,000.00View SEC Filing  
4/4/2016Gilla KaplanDirectorSell15,967$101.84$1,626,079.28View SEC Filing  
3/3/2016Michael W BonneyDirectorBuy2,000$103.01$206,020.00View SEC Filing  
2/22/2016James J LoughlinDirectorSell2,100$104.12$218,652.00View SEC Filing  
12/28/2015Ernest MarioDirectorSell40,000$119.36$4,774,400.00View SEC Filing  
12/23/2015Michael D CaseyDirectorSell20,000$122.11$2,442,200.00View SEC Filing  
12/21/2015Gilla KaplanDirectorSell14,464$110.62$1,600,007.68View SEC Filing  
9/10/2015Gilla KaplanDirectorSell15,000$122.45$1,836,750.00View SEC Filing  
9/8/2015Michael D. CaseyDirectorSell15,000$121.76$1,826,400.00View SEC Filing  
7/13/2015Thomas O DanielInsiderSell30,156$120.78$3,642,241.68View SEC Filing  
6/10/2015Gilla KaplanDirectorSell15,000$111.74$1,676,100.00View SEC Filing  
6/9/2015Michael D CaseyDirectorSell15,000$111.18$1,667,700.00View SEC Filing  
2/26/2015Gilla KaplanDirectorSell15,000$122.89$1,843,350.00View SEC Filing  
2/6/2015Mark J AllesInsiderSell117,099$120.68$14,131,507.32View SEC Filing  
1/15/2015Lawrence V SteinInsiderSell26,666$120.01$3,200,186.66View SEC Filing  
1/2/2015Gilla KaplanDirectorSell45,536$113.47$5,166,969.92View SEC Filing  
12/8/2014Gilla KaplanDirectorSell15,000$118.20$1,773,000.00View SEC Filing  
11/3/2014Robert J HuginInsiderSell158,000$106.68$16,855,440.00View SEC Filing  
10/27/2014Ernest MarioDirectorSell100,000$102.85$10,285,000.00View SEC Filing  
10/24/2014Michael D CaseyDirectorSell15,000$102.94$1,544,100.00View SEC Filing  
9/8/2014Gilla KaplanDirectorSell30,000$93.73$2,811,900.00View SEC Filing  
8/4/2014Perry A KarsenInsiderSell39,104$87.55$3,423,555.20View SEC Filing  
7/25/2014Richard W BarkerDirectorSell17,600$87.03$1,531,728.00View SEC Filing  
5/1/2014Perry KarsenInsiderSell11,922$146.78$1,749,911.16View SEC Filing  
3/4/2014Michael CaseyDirectorSell12,770$162.33$2,072,954.10View SEC Filing  
2/5/2014Ernest MarioDirectorSell13,500$151.87$2,050,245.00View SEC Filing  
12/23/2013Lawrence SteinInsiderSell12,062$168.19$2,028,707.78View SEC Filing  
10/25/2013Carrie Smith CoxDirectorSell18,750$157.67$2,956,312.50View SEC Filing  
9/4/2013Gilla KaplanDirectorSell15,000$143.92$2,158,800.00View SEC Filing  
8/28/2013Thomas DanielInsiderSell32,263$137.06$4,421,966.78View SEC Filing  
8/2/2013Perry A KarsenInsiderSell93,008$146.50$13,625,672.00View SEC Filing  
5/30/2013Robert J HuginInsiderSell68,087$123.58$8,414,191.46View SEC Filing  
5/29/2013Ernest MarioDirectorBuy1,000$123.72$123,720.00View SEC Filing  
5/28/2013Thomas O DanielInsiderSell32,959$124.91$4,116,908.69View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Celgene Corp. (NASDAQ:CELG)
News IconBiotech Stocks Worth a Closer Look: Celgene Corporation (NASDAQ:CELG), Sarepta Therapeutics, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:CELG)
voiceregistrar.com - September 28 at 3:59 PM
fool.com logoWill Celgene Depose Biogen to Become Top Dog In Multiple Sclerosis? (NASDAQ:CELG)
www.fool.com - September 28 at 11:43 AM
streetinsider.com logoCelgene (CELG) Announces Long-Term Safety Findings for OTEZLA in Psoriasis and Psoriatic Arthritis (NASDAQ:CELG)
www.streetinsider.com - September 28 at 8:55 AM
rttnews.com logoCelgene Presents OTEZLA Long-Term Safety Data In Psoriasis,Psoriatic Arthritis (NASDAQ:CELG)
www.rttnews.com - September 28 at 8:55 AM
finance.yahoo.com logoJulian Robertson: Biotech Stocks Are Cheap (NASDAQ:CELG)
finance.yahoo.com - September 28 at 8:55 AM
finance.yahoo.com logoOral OTEZLA® (apremilast) Long-Term Safety Data Presented at EADV Congress in Both Psoriasis and Psoriatic Arthritis (NASDAQ:CELG)
finance.yahoo.com - September 28 at 8:55 AM
finance.yahoo.com logo3:19 am Celgene presents long-term safety data for ESTEEM 1 and 2 and PALACE 1-3 trials showed no increase in incidence of adverse events, no new safety signals and improved tolerability (NASDAQ:CELG)
finance.yahoo.com - September 28 at 8:55 AM
News IconTop Gainers of the Day: Celgene Corporation (NASDAQ:CELG) from Biotechnology (NASDAQ:CELG)
twincountynews.com - September 27 at 4:05 PM
capitalcube.com logoCelgene Corp. – Value Analysis (NASDAQ:CELG) : September 27, 2016 (NASDAQ:CELG)
www.capitalcube.com - September 27 at 4:05 PM
blogs.barrons.com logoAmgen: The Blame Game (NASDAQ:CELG)
blogs.barrons.com - September 27 at 4:05 PM
News IconBiotech Stocks To Put On Your Watch List: Celgene Corporation (NASDAQ:CELG), Tesaro, Inc. (NASDAQ:TSRO) - The Voice Registrar (NASDAQ:CELG)
voiceregistrar.com - September 26 at 4:24 PM
News IconOwnership Change: Edgewood Management LLC Upped Holding in Celgene Corp (CELG) by $180.99 Million - Chester News (NASDAQ:CELG)
www.chesterindependent.com - September 26 at 8:53 AM
News IconS&P 500 Stocks to Buy and Hold for the Next 10 Years (NASDAQ:CELG)
portal.kiplinger.com - September 26 at 8:53 AM
News IconBiotechnology: Celgene Corporation (NASDAQ:CELG) Position of the day (NASDAQ:CELG)
twincountynews.com - September 24 at 4:00 PM
News IconStock in Limelight: Duke Realty Corporation (NYSE:DRE), Celgene Corporation (NASDAQ:CELG) - Newburgh Press (NASDAQ:CELG)
newburghpress.com - September 23 at 3:34 PM
benzinga.com logoMike Khouw Sees Unusual Options Activity In Celgene - Benzinga (NASDAQ:CELG)
www.benzinga.com - September 23 at 3:34 PM
marketrealist.com logoThe Factors behind Gilead’s Discounted Valuation (NASDAQ:CELG)
marketrealist.com - September 23 at 3:34 PM
News IconTime To Put On The Watch List? - Celgene Corporation (NASDAQ:CELG), Biogen Inc. (NASDAQ:BIIB) - The Voice Registrar (NASDAQ:CELG)
voiceregistrar.com - September 22 at 9:47 AM
News Icon3 Health Stocks to Own for the Next 10 Years (NASDAQ:CELG)
portal.kiplinger.com - September 22 at 9:47 AM
News IconLeading stocks in today’s market: Celgene Corporation (NASDAQ:CELG) (NASDAQ:CELG)
twincountynews.com - September 21 at 4:48 PM
fool.com logoThe Most Exciting Drug in Celgene's Pipeline (NASDAQ:CELG)
www.fool.com - September 21 at 4:39 PM
News IconStock in the Traders Limelight- Celgene Corporation's (CELG) (NASDAQ:CELG)
myhealthbowl.com - September 21 at 8:10 AM
News IconCelgene Corporation (NASDAQ:CELG) Analyst Estimates (NASDAQ:CELG)
thelakeandeswave.com - September 21 at 8:10 AM
News IconCelgene Corporation (CELG) Shares are Up 3.9% (NASDAQ:CELG)
magseriesusa.net - September 21 at 8:10 AM
News IconCelgene Corporation: CELG Stock Charts Are a Must-See (NASDAQ:CELG)
www.profitconfidential.com - September 21 at 8:10 AM
marketrealist.com logoOrphan Drug Designation among Latest Happenings at Ionis (NASDAQ:CELG)
marketrealist.com - September 21 at 8:10 AM
investorplace.com logoTrade of the Day: Celgene Corporation (CELG) Looking Healthy Again (NASDAQ:CELG)
investorplace.com - September 20 at 7:27 AM
News IconHigh Market Cap Stock of the Day – Celgene Corporation (NASDAQ:CELG) (NASDAQ:CELG)
twincountynews.com - September 19 at 4:56 PM
News IconVolatile Movements: Fiat Chrysler Automobiles NV(NYSE:FCAU), Celgene Corporation (NASDAQ:CELG), Concordia ... - NYSE Journal (press release) (NASDAQ:CELG)
stockznews.com - September 19 at 8:55 AM
News IconCelgene Displays Oral Ozanimod’s Efficacy and Safety from Phase 2 RADIANCE Clinical Trial for Relapsing Multiple Sclerosis (MS) (NASDAQ:CELG)
www.msunites.com - September 19 at 8:54 AM
247wallst.com logoRBC Says These 4 Top Biotechs Could Have Big Upside Potential (NASDAQ:CELG)
247wallst.com - September 19 at 8:54 AM
fool.com logo3 Top Stocks on Sale This Fall (NASDAQ:CELG)
www.fool.com - September 19 at 8:54 AM
businesswire.com logoOral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing ... - Business Wire (press release) (NASDAQ:CELG)
www.businesswire.com - September 17 at 8:56 AM
News IconOral Ozanimod Efficacy & Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing Multiple Sclerosis ... (NASDAQ:CELG)
ih.advfn.com - September 16 at 4:04 PM
thecountrycaller.com logoJefferies Expects Possible Deal For Celgene Corporation (CELG) With EngMab (NASDAQ:CELG)
www.thecountrycaller.com - September 16 at 4:04 PM
smarteranalyst.com logoCompany Update (NASDAQ:CELG): Celgene Reports Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial at 32nd ECTRIMS (NASDAQ:CELG)
www.smarteranalyst.com - September 16 at 4:04 PM
News IconIs Celgene Corporation (NASDAQ:CELG), a large market cap stock a smart buy? (NASDAQ:CELG)
twincountynews.com - September 16 at 4:04 PM
reuters.com logoBRIEF-Celgene Corp- releases data on Phase 2 RADIANCE trial (NASDAQ:CELG)
www.reuters.com - September 16 at 4:04 PM
News IconStock's Report of the Thursday - Celgene Corporation's (CELG) - Hot Stocks Point (NASDAQ:CELG)
www.hotstockspoint.com - September 16 at 4:04 PM
reuters.com logoBRIEF-Celgene Corp- releases data on Phase 2 RADIANCE trial - Reuters (NASDAQ:CELG)
in.reuters.com - September 16 at 4:04 PM
investopedia.com logoCelgene Outspends Big Pharmas in Deals (CELG) - Investopedia (NASDAQ:CELG)
www.investopedia.com - September 15 at 9:36 PM
investopedia.com logoCelgene's Big Bet May Pay Off (CELG) | Investopedia - Investopedia (NASDAQ:CELG)
www.investopedia.com - September 15 at 4:31 PM
investopedia.com logoCelgene’s Big Bet May Pay Off (CELG) (NASDAQ:CELG)
www.investopedia.com - September 15 at 4:31 PM
investopedia.com logoCelgene Outspends Big Pharmas in Deals (CELG) (NASDAQ:CELG)
www.investopedia.com - September 15 at 4:31 PM
News IconHot Biotech Stocks Recap: Clovis Oncology, Inc. (NASDAQ:CLVS), Celgene Corporation (NASDAQ:CELG) - The Voice Registrar (NASDAQ:CELG)
voiceregistrar.com - September 15 at 11:29 AM
News IconAnalysts Valuations For Two Stocks: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Celgene Corporation (NASDAQ ... - The Voice Registrar (NASDAQ:CELG)
voiceregistrar.com - September 15 at 11:29 AM
fool.com logo5 Reasons Celgene Is a Buy - Motley Fool (NASDAQ:CELG)
www.fool.com - September 15 at 11:29 AM
fool.com logo5 Reasons Celgene Is a Buy (NASDAQ:CELG)
www.fool.com - September 15 at 11:22 AM
stocksdaily.net logoCelgene Corporation (NASDAQ:CELG) Rating At 1.35 - Stocks Daily (NASDAQ:CELG)
www.stocksdaily.net - September 14 at 9:24 PM
News IconSummit Company Sponsoring First Ever Psoriatic Arthritis Awareness Day (NASDAQ:CELG)
patch.com - September 14 at 9:24 PM


Celgene Corp. (NASDAQ:CELG) Chart for Thursday, September, 29, 2016

Last Updated on 9/29/2016 by MarketBeat.com Staff